Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Nuevos tratamientos combinados en distintas fases de la cirrosis hepática con hipertensión portal

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT14/00113
Duration: 20/05/2015 - 19/05/2016

Papel de la elastografía hepática y esplénica en el diagnóstico, seguimiento y tratamiento de la enfermedad crónica hepática avanzada.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI14/00152
Duration: 01/01/2015 - 31/12/2018

Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis Molecular Subtypes for Targeted Therapies in Alcoholic Hepatittis U01 AA021908-01

IP: -
Collaborators: Joan Genescà Ferrer
Funding agency: National Institutes of Health (NIH)
Funding: 94320
Reference: INTEAM_NIH-NIAAA2013
Duration: 01/06/2013 - 31/12/2018

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Jesús Francisco Lopez Lozano

Jesús Francisco Lopez Lozano

Read more
Jorge Serra Pueyo

Jorge Serra Pueyo

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.